Tesetaxel, Administered Orally as a Single Agent, Results in 45% Confirmed Response Rate in Patients with HER2 Negative, Hormone Receptor Positive, Metastatic Breast Cancer

KeepHealthCare.ORG – Tesetaxel, Administered Orally as a Single Agent, Results in 45% Confirmed Response Rate in Patients with HER2 Negative, Hormone Receptor Positive, Metastatic Breast Cancer CHICAGO–(BUSINESS WIRE)–Odonate Therapeutics, Inc. Continue reading